APA Zitierstil

Clifton, G. T., Peace, K. M., Holmes, J. P., Vreeland, T. J., Hale, D. F., Herbert, G. S., . . . Mittendorf Elizabeth, A. (2019). Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors. Clinical immunology (Orlando, Fla.), 201, 48. https://doi.org/10.1016/j.clim.2019.02.011

Chicago Zitierstil

Clifton, G Travis, et al. "Initial Safety Analysis of a Randomized Phase II Trial of Nelipepimut-S + GM-CSF and Trastuzumab Compared to Trastuzumab Alone to Prevent Recurrence in Breast Cancer Patients with HER2 Low-expressing Tumors." Clinical Immunology (Orlando, Fla.) 201 (2019): 48. https://dx.doi.org/10.1016/j.clim.2019.02.011.

MLA Zitierstil

Clifton, G Travis, et al. "Initial Safety Analysis of a Randomized Phase II Trial of Nelipepimut-S + GM-CSF and Trastuzumab Compared to Trastuzumab Alone to Prevent Recurrence in Breast Cancer Patients with HER2 Low-expressing Tumors." Clinical Immunology (Orlando, Fla.), vol. 201, 2019, p. 48.